arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


 
CRITICAL PAPERS IN THE MANAGEMENT OF MACULAR EDEMA IN RETINAL AND UVEITIC DISEASES

Presented by the Johns Hopkins University School of Medicine.

This educational activity is supported by an educational grant from Allergan Inc.

GOAL

To provide retina specialists and comprehensive ophthalmologists with up-to-date information on the treatment and management of retinal and uveitic diseases.

INTENDED AUDIENCE

This activity is designed for retina specialists and comprehensive ophthalmologists in the United States. No prerequisites required.

LEARNING OBJECTIVE

After completing this activity, the participant should be able to:

  • Assess clinical trial results on the management of retinal diseases and uveitis.
  • Practice optimal application of best evidence during clinical case scenarios.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 2 AMA PRA Category I Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The estimated time to complete this educational activity: 2 hours.

Release date: February 10, 2013. Expiration date: February 10, 2015.

HOW TO CLAIM CREDIT

Please complete a brief pre-assessment before continuing with the monograph. After reading this monograph, participants may receive credit by completing the CME test and evaluation online, and receiving a score of 70% or higher.

Faculty
Full Disclosure Policy Affecting CME Activities:
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

COURSE DIRECTOR
Quan Dong Nguyen, MD, MSc

Associate Professor of Ophthalmology
Retina Division
Diseases of the Retina and Vitreous, and Uveitis
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

PARTICIPATING FACULTY
Julia A. Haller, MD

Ophthalmologist-in-Chief
The William Tasman MD Endowed Chair in Ophthalmology
Wills Eye Institute
Professor and Chair of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania

Judy E. Kim, MD
Professor of Ophthalmology
Eye Institute
Medical College of Wisconsin
Milwaukee, Wisconsin

Baruch D. Kuppermann, MD, PhD
Professor of Ophthalmology and Biomedical Engineering
Chief, Retina Service
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, California

Participating Faculty Disclosures
Dr Haller reports serving as a consultant for Allergan, Inc; and holding stock options in OptiMedica.

Dr Kim reports serving as an advisor for Alimera Sciences.

Dr Kuppermann reports receiving grants from Alimera Sciences, Allergan, Inc, Genentech, Inc, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc, and ThromboGenics, Inc; and serving as a consultant for Alimera Sciences, Allegro, Allergan, Inc, Fovea Pharmaceuticals, Genentech, Inc, Glaukos, NeoVista, Inc, Novagali Pharma, Novartis, Ophthotech, Regeneron Pharmaceuticals, Inc, ThromboGenics, Inc, and 2C Tech Corporation, Inc.

Dr Nguyen reports serving as a principal investigator on grants from Abbott Laboratories, Genentech, Inc, Lux Biosciences, Inc, Pfizer Inc, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co, Ltd; and serving as a consultant for Bausch & Lomb Incorporated and Santen Pharmaceutical Co, Ltd. Dr Nguyen spouse, Diana V. Do, MD, reports the relationships listed below.

Planner Disclosures
Planning Committee: Quan Dong Nguyen, MD, MSc; Diana V. Do, MD; Joy P. Marko, MS, APN-C, CCMEP.

Dr Nguyen reports serving as a principal investigator on grants from Abbott Laboratories, Genentech, Inc, Lux Biosciences, Inc, Pfizer Inc, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co, Ltd; and serving as a consultant for Bausch & Lomb Incorporated and Santen Pharmaceutical Co, Ltd. Dr Nguyen spouse, Diana V. Do, MD, reports the relationships listed below.

Dr Do reports serving as a principal investigator on grants from Genentech, Inc, and Regeneron Pharmaceuticals, Inc; and participating in an advisory board and receiving honoraria from ISTA Pharmaceuticals. Dr Do’s spouse, Quan Dong Nguyen, MD, MSc, reports the relationships listed above.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

Dr Kim: bevacizumab and intravitreal steroid injection.

Dr Kuppermann: aflibercept and triamcinolone acetonide for retinal vein occlusion.

Dr Haller: bevacizumab and triamcinolone acetonide.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

Confidentiality Disclaimer for CME Activity Participant

I certify that I am participating in a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office (410) 955-2959 or e-mail cmenet@jhmi.edu.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (Updated 4/09)

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY

Instructions
The following activity consists of 3 sections: an unaccredited pre-test, a monograph, and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit.


Pre-Test

Overview
Updates on the Management of Macular Edema in Retinal and Uveitic Diseases


Critical Papers In. . .

  Diabetic Macular Edema

  Retinal Vein Occlusion

  Uveitis

Post-Test
procced to pretest
footer